Join your colleagues for an educational program on The Role of Individualized Treatment in the Management of Hereditary Angioedema (HAE)

Please join Dr. Gower in a dynamic discussion about HAE and different treatments. This presentation and interactive Q&A session will review:

- Clinical manifestations and pathophysiology of HAE
- Importance of timely diagnosis
- Current guidelines for the management of HAE
- The role of C1-INH therapy in routine prophylaxis
- The role of an on-demand therapy in treating symptoms of an acute attack
- Important Safety Information for both CINRYZE and FIRAZYR

Who: Richard G. Gower, MD
Allergist/Immunologist
Marycliff Allergy Specialists
Spokane, WA

When: Friday, June 24, 2016
1:00 PM

Where: The Hotel Hershey
100 Hotel Road
Hershey, PA 17033
(717) 533-2171

For questions about the program or to register, please call toll-free 877-761-7925.

To facilitate a meaningful educational discussion, this program is open to healthcare professionals only. Please be advised that spouses and other guests are not permitted to attend. Thank you in advance, and we look forward to your participation.

This is not a CME program.

FIRAZYR® (icatibant injection) Indication
FIRAZYR is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.

Important Safety Information
Warnings and precautions
Given the potential for airway obstruction during acute laryngeal HAE attacks, patients should be advised to seek medical attention in an appropriate healthcare facility immediately in addition to treatment with FIRAZYR.

CINRYZE® (C1 esterase inhibitor [human]) Indication
CINRYZE is indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE).

Important Safety Information
CINRYZE is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product.

Please see additional Important Safety Information on the reverse, and the accompanying full Prescribing Information for both products.
Adverse Reactions
The most commonly reported adverse reactions were injection-site reactions, which occurred in almost all patients (97%) in clinical trials. These injection-site reactions included bruising, hematoma, burning, erythema, hypoesthesia, irritation, numbness, edema, pain, pressure sensation, pruritus, swelling, urticaria, and warmth. Other common adverse reactions included pyrexia (4%), transaminase increase (4%), and dizziness (3%), as well as rash, headache, and nausea.

Drug Interactions
FIRAZYR is a bradykinin B2 receptor antagonist and thereby has the potential to have a pharmacodynamic interaction with ACE inhibitors where FIRAZYR may attenuate the antihypertensive effect of ACE inhibitors. Clinical trials to date have excluded subjects taking ACE inhibitors.

Use in Specific Populations
FIRAZYR is classified as pregnancy category C.

There are no adequate and well-controlled studies of FIRAZYR in pregnant women. FIRAZYR should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Because many drugs are excreted in human milk, caution should be exercised when FIRAZYR is administered to a nursing woman.

Clinical studies of FIRAZYR included a limited number of subjects aged 65 and over. Elderly patients are likely to have increased systemic exposure. Reported clinical experience has not identified differences in efficacy and safety between elderly and younger patients.

Safety and effectiveness in patients below 18 years of age have not been established.

Self-administration
The safety of self-administration was evaluated in a separate, open-label trial in 56 patients with HAE. In this trial, the safety profile of FIRAZYR in patients who self-administered FIRAZYR was similar in nature and frequency to that of patients whose therapy was administered by healthcare professionals.

Please see full Prescribing Information.

To report suspected adverse events, please contact Shire Human Genetic Therapies, Inc. at 1-866-888-0660 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

For assistance with medical inquiries about FIRAZYR, please contact Medical Information at 1-866-888-0660 option 2 or US_ShireHGT_MedicalInformation@shire.com.

Promotional program sponsored by Shire.